Table 3. Univariate and multivariate analysis of time to progression (log-rank test) for irinotecan-based chemotherapy.
| Univariate analysis |
|
|
|
|---|---|---|---|
| Clinical parameter | n | Median time to progression (months) | p value |
|
Age |
|
|
|
| < 75 y |
79 |
11 |
0.9099 |
| ≥ 75 y |
1 |
- |
|
|
Gender |
|
|
|
| Male |
48 |
12 |
0.1598 |
| Female |
32 |
9 |
|
|
Primary tumor localization |
|
|
|
| Sigmoid colon |
27 |
11 |
0.644 |
| Colon/Rectum |
53 |
10.1 |
|
|
WHO performance status |
|
|
|
| • 0–1 |
79 |
11 |
0.3185 |
| • 2–3 |
1 |
- |
|
|
Karnofsky performance status |
|
|
|
| ≤ 80 |
79 |
- |
0.3185 |
| > 80 |
1 |
11 |
|
|
B-Raf gene mutation status |
|
|
|
| Mutation |
4 |
10.5 |
0.2909 |
| Wild-type |
69 |
11 |
|
|
K-Ras gene mutation status |
|
|
|
| Mutation |
4 |
9 |
0.05883 |
| Wild-type |
76 |
11 |
|
|
Pretreatment CEA level (ng/ml) |
|
|
|
| ≤ 5 |
38 |
13 |
0.0085 |
| > 5 |
40 |
9 |
|
|
Resection of metastases |
|
|
|
| Yes |
27 |
14 |
0.0131 |
| No | 53 | 9 |
| Multivariate analysis |
|
|
|
|---|---|---|---|
| Clinical parameter | HR (95% CI) | p value | |
|
Histological type |
|
|
|
| Tubular vs. others |
NS |
> 0.05 |
|
|
K-Ras gene mutation status |
|
|
|
| Mutation vs. wild-type |
0.59 (0.25-.099) |
0.0459 |
|
|
B-Raf gene mutation status |
|
|
|
| Mutation vs. wild-type |
NS |
> 0.05 |
|
|
Pre-treatment CEA level (ng/ml) |
|
|
|
| ≤ 5 vs. > 5 | 0.52(0.33–0.83) | 0.0065 |
NS, not significant.